Robert Bissonnette, MD: Safety Profile, Future Research on New Oral IL-23 Inhibitor for Psoriasis

During this segment of his interview, Bissonnette discussed safety data on JNJ-2113 for patients with plaque psoriasis and later went into future research topics.

Related Keywords

Robert Bissonnette ,Innovaderm Research ,Chief Executive Officer ,Il 23 ,Coral ,Inhibitor ,Jnj 2113 ,Jnj ,Bissonnette ,Interview ,Safety ,Phase ,Psoriasis ,